헬리코박터 파일로리 비침습적 검사 시장 : 검사 유형, 기술, 검사 방법, 최종 사용자, 서비스 형태, 용도별 예측(2026-2032년)

The Helicobacter Pylori Non-invasive Testing Market is projected to grow by USD 520.79 million at a CAGR of 7.73% by 2032.

Helicobacter pylori non-invasive testing is becoming central to gastrointestinal care because H. pylori infection is one of the most common chronic bacterial infections worldwide and is a recognized cause of peptic ulcer disease, chronic gastritis, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The World Health Organization and the International Agency for Research on Cancer classify H. pylori as a Group 1 carcinogen, reinforcing the clinical need for accurate detection, eradication monitoring, and population-level gastric cancer risk management.

The industry is shaped by rising use of urea breath tests, stool antigen tests, and laboratory-based serology in defined clinical pathways. Urea breath testing and monoclonal stool antigen testing are widely used to identify active infection, while post-treatment test-of-cure strategies are increasingly aligned with evidence-based gastroenterology guidelines, including recommendations to confirm eradication after therapy. Demand is expanding as health systems prioritize early diagnosis, antimicrobial stewardship, non-endoscopic testing options, and patient-friendly access across primary care, gastroenterology, and outpatient diagnostic settings.

Transformative Shifts Reshaping H. pylori Testing

The Helicobacter pylori non-invasive testing landscape is shifting from episodic diagnosis toward guideline-driven screening, confirmation, and treatment monitoring. Clinical practice has moved away from relying on symptoms alone because dyspepsia, peptic ulcer disease, and gastric cancer risk require objective testing. Non-invasive H. pylori diagnostics are also gaining relevance as endoscopy capacity remains limited in many health systems and payers seek lower-cost, scalable testing pathways for appropriate patients.

Another major shift is the growing emphasis on diagnostic accuracy and antibiotic resistance management. Consensus guidelines increasingly recommend confirming eradication after therapy, creating recurring demand for urea breath tests and stool antigen tests that detect active infection. At the same time, laboratories and diagnostic providers are investing in automation, digital ordering, sample logistics, electronic reporting, and integrated clinical workflows to reduce turnaround times and support primary care, gastroenterology, and public health programs.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence H. pylori non-invasive testing through workflow optimization, risk stratification, quality management, and decision support rather than replacing validated assays. AI-enabled systems can help identify patients who meet guideline-based testing criteria by analyzing electronic health records for dyspepsia, ulcer history, prior eradication therapy, gastric cancer risk factors, family history, medication exposure, and factors that may affect test performance, including proton pump inhibitors, antibiotics, and bismuth compounds.

The cumulative impact is strongest where AI is connected to laboratory information systems, population health platforms, and clinical decision support. Machine learning can support demand planning, flag incomplete test-of-cure follow-up, improve patient reminders, and assist laboratories in monitoring pre-analytical and operational quality indicators. However, adoption depends on transparent validation, data governance, regulatory oversight, and clinician trust, particularly because diagnostic decisions must remain anchored in analytically and clinically validated urea breath, stool antigen, serology, or molecular testing methods.

Key Regional Insights Across Global Markets

Asia-Pacific represents a high-priority region for Helicobacter pylori non-invasive testing due to large population size, substantial gastric cancer burden in several countries, and expanding access to outpatient diagnostics. Japan, South Korea, and China maintain strong clinical attention to gastric cancer prevention and digestive disease management, while India and Southeast Asian countries are improving diagnostic access through public and private healthcare expansion. North America continues to show strong demand through established gastroenterology guidelines, insurance coverage, centralized laboratories, digital ordering systems, and broad adoption of urea breath and stool antigen testing for active infection and eradication confirmation.

Latin America and Europe are advancing through improved diagnostic access and stronger adherence to evidence-based management of dyspepsia, peptic ulcer disease, and post-treatment confirmation. Europe benefits from consensus-led clinical practice, laboratory quality standards, and organized care pathways, while Latin America has meaningful opportunity as awareness, private diagnostic networks, and affordability improve. The Middle East is supported by healthcare infrastructure modernization, rising investment in hospital-based diagnostics, and growing use of non-invasive gastrointestinal testing, whereas Africa remains a long-term access opportunity where cost-effective stool antigen testing, decentralized sample collection, and clinician education can help address underdiagnosis and uneven laboratory availability.

Key Group Insights Across Economic and Policy Blocs

ASEAN markets are gaining momentum as urban healthcare access, private diagnostic networks, and awareness of gastrointestinal disease continue to improve across countries with diverse reimbursement and laboratory maturity. The GCC benefits from high healthcare spending, hospital modernization, specialist care expansion, and medical tourism, which support premium non-invasive H. pylori testing pathways. The European Union remains one of the most structured environments for H. pylori diagnostics due to harmonized quality expectations, clinician adoption of consensus recommendations, laboratory accreditation practices, and reimbursement frameworks in several member states.

BRICS economies combine large patient pools with rising diagnostic capacity, making them essential to long-term utilization of non-invasive testing for dyspepsia management, peptic ulcer disease, and gastric cancer risk reduction. G7 markets lead in guideline implementation, laboratory automation, digital health integration, and test-of-cure adoption, supporting higher-value diagnostic utilization. NATO countries overlap significantly with advanced European and North American healthcare systems, where procurement standards, clinical governance, interoperability, and secure health data infrastructure can accelerate adoption of accurate, non-invasive H. pylori testing solutions.

Key Country Insights for Priority Markets

The United States is a major market for Helicobacter pylori non-invasive testing because clinical guidelines support testing in dyspepsia, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, selected gastric cancer risk contexts, and post-treatment confirmation. Canada shows similar evidence-based adoption supported by primary care and specialist pathways, while Mexico and Brazil offer growth through expanding private laboratories, hospital networks, and broader access to affordable stool antigen and breath testing. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established clinical pathways, laboratory infrastructure, and evidence-based dyspepsia management, while Russia presents demand linked to gastric disease burden and ongoing laboratory modernization.

China and Japan are highly relevant because of gastric cancer prevention priorities, aging populations, and large-scale digestive disease management, with Japan maintaining strong clinical awareness of H. pylori eradication and post-treatment assessment. India offers significant long-term potential due to population size, high digestive disease presentation, and improving diagnostics access, although affordability, awareness, and standardized testing pathways remain important. Australia and South Korea demonstrate mature adoption patterns, supported by developed healthcare systems, gastroenterology expertise, clinical guideline use, and strong reliance on validated non-invasive testing for active infection and treatment follow-up.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated assays that detect active H. pylori infection, especially urea breath tests and monoclonal stool antigen tests, while clearly positioning serology for limited use cases where active infection confirmation is not required or where local clinical protocols support its use. Commercial and clinical strategies should emphasize guideline alignment, test-of-cure compliance, appropriate patient preparation, and education on factors that can cause false-negative results, including recent antibiotics, bismuth compounds, or proton pump inhibitor use.

Manufacturers, laboratories, and healthcare providers should invest in digital ordering, home sample collection where appropriate, patient reminders, clear pre-test instructions, and integrated reporting that supports treatment follow-up. Partnerships with gastroenterologists, primary care networks, payers, and public health stakeholders can expand appropriate utilization and reduce unnecessary endoscopy in suitable patients. In emerging markets, affordability, distribution reliability, sample stability, and clinician training will be decisive, while in mature markets differentiation will depend on accuracy, convenience, turnaround time, interoperability, and evidence demonstrating improved care pathway performance.

Research Methodology

This executive summary is based on secondary research from publicly available clinical guidelines, epidemiology literature, regulatory principles, healthcare policy sources, and peer-reviewed evidence on H. pylori diagnosis and management. Key inputs include global disease burden patterns, the established association between H. pylori and gastric cancer, and guideline-supported use of urea breath tests and stool antigen tests for active infection and eradication confirmation.

The analysis applies a triangulated research approach that evaluates clinical utility, diagnostic performance, market accessibility, regional healthcare infrastructure, reimbursement maturity, laboratory workflow trends, and technology adoption. Insights are framed for strategic decision-making and avoid unsupported market sizing, market share, or forecasting claims. All observations are aligned with evidence-based diagnostic practice and the known limitations of non-invasive testing modalities, including medication-related false negatives and the limited ability of serology to distinguish active from past infection.

Conclusion and Strategic Outlook

The Helicobacter pylori non-invasive testing industry is positioned for sustained strategic relevance as health systems focus on early diagnosis, gastric cancer risk reduction, peptic ulcer disease management, antimicrobial stewardship, and confirmation of eradication after therapy. Non-invasive approaches reduce dependence on endoscopy for many appropriate patients and support scalable gastrointestinal care across both mature and emerging healthcare environments.

Future competitiveness will depend on diagnostic accuracy, ease of use, reimbursement access, patient preparation, turnaround time, and integration into clinical workflows. Organizations that combine validated H. pylori testing with digital follow-up, clinician education, antimicrobial stewardship, and region-specific access models will be best positioned to meet clinical demand. As awareness rises, H. pylori non-invasive testing will remain a critical component of preventive gastroenterology and evidence-based digestive health management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Helicobacter Pylori Non-invasive Testing Market, by Test Type

• 7.1. Serology Test
  • 7.1.1. IgG Antibody Test
  • 7.1.2. IgA Antibody Test
  • 7.1.3. IgM Antibody Test
• 7.2. Stool Antigen Test
  • 7.2.1. Monoclonal Antibody Test
  • 7.2.2. Polyclonal Antibody Test
• 7.3. Urea Breath Test
  • 7.3.1. Carbon-13 Urea Breath Test
  • 7.3.2. Carbon-14 Urea Breath Test
• 7.4. Molecular Test
• 7.5. Saliva Test

8. Helicobacter Pylori Non-invasive Testing Market, by Technology

• 8.1. Immunoassay
  • 8.1.1. Enzyme-Linked Immunosorbent Assay
  • 8.1.2. Lateral Flow Immunoassay
  • 8.1.3. Chemiluminescent Immunoassay
• 8.2. Infrared Spectrometry
• 8.3. Mass Spectrometry
• 8.4. Polymerase Chain Reaction
• 8.5. Biosensor

9. Helicobacter Pylori Non-invasive Testing Market, by Test Method

• 9.1. Laboratory-Based Test
• 9.2. Point-Of-Care Test

10. Helicobacter Pylori Non-invasive Testing Market, by End User

• 10.1. Clinics
• 10.2. Diagnostic Laboratories
• 10.3. Hospitals

11. Helicobacter Pylori Non-invasive Testing Market, by Mode Of Service

• 11.1. Analyzer-Based Onsite Testing
• 11.2. Kit-Based Decentralized Testing
• 11.3. Central Laboratory Send-Out Testing

12. Helicobacter Pylori Non-invasive Testing Market, by Application

• 12.1. Initial Diagnosis
• 12.2. Post-Treatment Confirmation
• 12.3. Population Screening
• 12.4. Antimicrobial Resistance Assessment

13. Helicobacter Pylori Non-invasive Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Helicobacter Pylori Non-invasive Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Helicobacter Pylori Non-invasive Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. ACON Laboratories, Inc.
• 17.3. Applied Biotech, Inc.
• 17.4. Artron Laboratories Inc.
• 17.5. ARUP Laboratories
• 17.6. Bio-Rad Laboratories, Inc.
• 17.7. Biohit HealthCare Ltd.
• 17.8. Biohit Oyj
• 17.9. Biomerica, Inc.
• 17.10. CerTest Biotec S.L.
• 17.11. Coris BioConcept SPRL
• 17.12. CTK Biotech, Inc.
• 17.13. Danaher Corporation
• 17.14. DiaSorin S.p.A.
• 17.15. DRG International, Inc.
• 17.16. Epitope Diagnostics, Inc.
• 17.17. EUROIMMUN Medizinische Labordiagnostika AG
• 17.18. F. Hoffmann-La Roche AG
• 17.19. Guangzhou Wondfo Biotech Co., Ltd.
• 17.20. Hangzhou AllTest Biotech Co., Ltd.
• 17.21. Healgen Scientific LLC
• 17.22. Kibion AB
• 17.23. Laboratory Corporation Of America Holdings
• 17.24. Meridian Bioscience, Inc.
• 17.25. MP Biomedicals, LLC
• 17.26. Otsuka America Pharmaceutical, Inc.
• 17.27. Quest Diagnostics Incorporated
• 17.28. Sekisui Diagnostics, LLC
• 17.29. Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
• 17.30. Siemens Healthineers AG
• 17.31. Thermo Fisher Scientific Inc.
• 17.32. Trinity Biotech plc
• 17.33. Vircell, S.L.
• 17.34. Zhejiang Orient Gene Biotech Co., Ltd.